Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03432260 · ClinicalTrials.gov registry record · Phase 2
A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis
A Phase 2 study, sponsored by Durect.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT03432260 is a Phase 2 study that has completed, run by Durect. The registered enrollment target is 19 participants.
The verdict
NCT03432260, a Phase 2 study, has completed, sponsored by Durect.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a research trial testing DUR-928 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of DUR 928 in patients with moderate and severe alcoholic hepatitis (AH).
Interventions
- DRUG DUR-928 30 mg
- DRUG DUR-928 90 mg
- DRUG DUR-928 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2019-09-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03432260
The ClinicalTrials.gov registry entry for NCT03432260 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Durect, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which DUR-928 30 mg is the first listed.
NCT03432260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03432260 about?
NCT03432260 is a clinical study titled "A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis". This is a research trial testing DUR-928 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of DUR 928 in patients with moderate and severe alcoholic hepatitis (AH).
What is the current status of trial NCT03432260?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2018-04-18. Estimated completion is 2019-09-09.
What interventions are being tested in trial NCT03432260?
The interventions under investigation include: DUR-928 30 mg (DRUG), DUR-928 90 mg (DRUG), DUR-928 150 mg (DRUG).
Who is sponsoring clinical trial NCT03432260?
This trial is sponsored by Durect, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.